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Abstract In order to identify the optimal target sites for
antisense oligonucleotides in the human multiple drug resistance
mRNA, the secondary structure of the 5P-terminal part of this
mRNA (nucleotides 1^678) was investigated. By using results of
probing with ribonucleases T1, ONE and V1 and results
of computer simulations, a model of the 5P-region of the
PGY1/MDR1 mRNA was built. The molecule is formed by
three major domains comprising several hairpins separated by
single-stranded fragments. The predicted single-stranded regions
of the PGY1/MDR1 mRNA efficiently bind complementary
oligonucleotides. ß 2000 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights re-
served.
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1. Introduction
Multidrug resistance (MDR) associated with simultaneous
development of cellular cross-resistance to the structurally and
functionally unrelated lipophilic drugs is the major obstacle
for cancer chemotherapy [1]. This phenotype is characterized
by overexpression of the PGY1/MDR1 gene, which encodes a
plasma membrane 170 kDa glycoprotein, called P-glycopro-
tein (P-gp) [2]. P-gp is assumed to act as an energy-dependent
drug-e¥ux pump involved in the control of cellular drug ac-
cumulation. Attempts to circumvent MDR are often focused
to inhibitors of a P-gp function. It is known that many agents
including the calcium channel blocker verapamil [3], immuno-
suppressor cyclosporin A [4] and oestrogen antagonist tamox-
ifen can circumvent the MDR [5,6]. However, the clinical use
of these compounds has its limitation as the toxicity and lack
of speci¢city [7].
Antisense oligonucleotides are considered as promising
therapeutics capable of down regulating speci¢c gene expres-
sions [8]. Attempts have been made to use the antisense ap-
proach to overcome the cellular MDR [9^11], however the
tested oligonucleotides did not show su⁄cient inhibiting ac-
tivity.
Selection of target sequences for antisense oligonucleotides
in mRNA is the key step in the development of antisense
constructs. Existing approaches to computing RNA structure
do not provide unambiguous predictions of optimal targets in
RNAs for antisense oligonucleotides. The currently used ap-
proaches are based on the empirical screening of a great num-
ber of oligonucleotides and on testing of oligonucleotides
binding to RNA detected by various techniques: gel shift
analysis [12] or binding to oligonucleotide arrays [13^15].
The oligonucleotides hybridization sites can be revealed by
ribonuclease (RNase) H digestion [10,16^18]. In spite of the
fact that combinatorial and semi-combinatorial approaches
are potentially powerful and allow simultaneous assessment
of a great number of oligonucleotides within the given RNA
sequence [14], all these methods are limited by various factors
as the hybridization conditions [13], the complexity of ob-
tained oligonucleotide pools [17], and steric problems arising
from the hybridization of structured RNAs with oligonucleo-
tide arrays [19].
To develop antisense oligonucleotides to PGY1/MDR1
mRNA, we investigated the structure of the 5P-proximal re-
gion of this mRNA by enzymatic probing and built a model
of this RNA using the probing and computer simulations
data. We have found that the single-stranded sequences pre-
dicted by our model are accessible for complementary oligo-
nucleotides. The proposed mRNA structure explains the data
of early studies on targeting PGY1/MDR1 RNA with oligo-
nucleotides.
2. Materials and methods
2.1. Oligonucleotides
Oligonucleotides 130-RT 5P-CCATCCCGACCTCG (complementa-
ry sequence 130^143), 240-RT 5P-GACTGACAGTTG (235^246),
340-RT 5P-CACCAGCATCATG (341^353), 450-RT 5P-CCTCCA-
GATTCATG (452^465), 560-RT 5P-GTCTTCCAGCTGCC (554^
566), 660-RT 5P-AGACATCATCTGTAAG (659^678), AS-1 5P-GA-
CCTCGCGCTCCTTG (122^137), AS-2 5P-CATTGCGGTCCCCT-
TC (150^165), AS-3 5P-GTCCAGCCCCATGGA (319^333) were syn-
thesized by standard phosphoramidite chemistry and puri¢ed by ion-
exchange and reverse-phase high performance liquid chromatography.
The oligonucleotides were homogeneous as assayed by 15% poly-
acrylamide gel electrophoresis (PAGE) in denaturing conditions fol-
lowed by staining with Stains-All [20].
2.2. Enzymatic probing of the in vitro transcript of the PGY1/MDR1
mRNA fragment
The 678 nucleotides PGY1/MDR1 mRNA fragment (one PGY1/
MDR1 mRNA transcription initiation site), corresponding to nucleo-
tides 3140 to +538 (+1 is the A of the P-gp translation initiation
codon), was obtained by in vitro transcription using T7 RNA poly-
merase and plasmid pMDR-670 [21], linearized with restriction en-
zyme SmaI, as a template, according to the protocol described in [22].
The transcript was puri¢ed by size-exclusion chromatography using
‘Speen-column’ (Sigma), ethanol-precipitated and dissolved in MilliQ
water.
In vitro transcript of PGY1/MDR1 mRNA was probed with RNase
T1 [23], RNase ONE [24] and RNase V1 [25] (Promega). Reactions
were carried out at 25‡C in 20 Wl 50 mM HEPES, pH 7.0, containing
200 mM KCl, 5 mM MgCl2, 200 Wg/ml in vitro transcript PGY1/
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MDR1 mRNA and 1 mg/ml total yeast tRNA as carrier. Incubation
time was 15 min for RNase ONE (0.03^0.5 U/ml) and T1 (0.05^1
U/ml), and 10 min for RNase V1 (0.01^0.5 U/ml).
Sites of enzymatic cleavages were determined by primer-directed
reverse transcription as described in [26] using 5P-32P-labeled oligonu-
cleotides 130-RT, 240-RT, 340-RT, 450-RT, 560-RT and 660-RT, as
primers. The products of primer extension were fractionated on 6% or
8% polyacrylamide gel containing 8 M urea.
2.3. Prediction of the PGY1/MDR1 mRNA secondary structure
RNA secondary structures were calculated using MFOLD subrou-
tine of the GCG software package [27,28] based on free energy min-
imization algorithm. Calculations were performed at 37‡C.
2.4. Hybridization of in vitro transcript of PGY1/MDR1 mRNA with
antisense oligonucleotides
Binding of oligonucleotides AS-1, AS-2, AS-3 to the in vitro tran-
script of the PGY1/MDR1 mRNA was investigated using a £uoro-
metric titration assay at 37‡C in 50 mM HEPES pH 7.5, containing
5 mM MgCl2, 200 mM KCl, 0.5 mM EDTA. Oligonucleotides were
5P-end-labeled with pyrene according to described procedures [29].
Pyrene was excited at 343 nm and £uorescence emission was moni-
tored at 382 nm using an MPF4 Hitachi spectro£uorimeter. Upon
stoichiometric binding of pyrene-labeled oligonucleotide to RNA, pyr-
ene £uorescence increases allowing to determine the equilibrium bind-
ing constant according to a modi¢ed Shtern^Folmer equation [30].
3. Results
The investigated 678 nucleotides in vitro transcript of the
PGY1/MDR1 mRNA includes the 5P-non-coding regulatory
region (3140; 31), P-gp translation initiation codon and a
fragment of the coding region (+1; +538). To identify single-
stranded and double-stranded sequences in this RNA, we in-
vestigated cleavage of the RNA with RNases ONE and T1
and RNase V1. The cleavage patterns were visualized by
primer-directed reverse transcription followed by electropho-
resis of the cDNA products [26]. In order to detect positions
on the template at which the reverse transcriptase pauses or
stops artefactually incubation controls were processed in par-
allel with the samples treated with RNases. Some of these
stops are thought to be the result from spontaneous RNA
hydrolysis, which occurs most frequently at pyrimidine^ad-
enine phosphodiester bonds and may show intrinsic fragility
of RNA at these sites [31]. Others are probably due to pausing
of the reverse transcriptase in highly structured regions of the
RNA template [26]. Representative autoradiographs of the
structure probing experiments are shown in Fig. 1.
Three alternative folds of the 5P-proximal 678 nucleotides of
the PGY1/MDR1 mRNA were obtained by computer simula-
tion. The secondary structure model that maximally ¢ts the
experimental data is shown in Fig. 2. The RNA chain folds
into a hairpin structure that forms three distinct domains:
domain I comprises nucleotides 1^280, domain II is formed
by nucleotides 281^569 and domain III by nucleotides 570^
678 (Fig. 2).
Domain I includes three hairpins containing 8^20 nucleo-
tides long terminal and internal loops. The stem-loop struc-
ture (nucleotides 1^53) consists of helix (8^19/53^42) closed by
a large loop (20^41). Although positions 20^41 are sensitive to
RNases T1 and ONE scissions, the possibility of base-pairing
within this loop cannot be excluded. Nucleotides 54^228 form
the long stem-loop structure containing double-stranded re-
gions sensitive to RNase V1 (54^61/221^228, 65^74/208^218,
87^94/176^183) and several internal loops (75^86, 95^110) re-
active to RNases ONE and T1 as shown in Fig. 1. The P-gp
translation initiation site is located within the hexanucleotide
terminal loop sensitive to RNases T1 and ONE (nucleotides
137^144). In addition, the mentioned positions, sequences
118^130, 151^154, 161^179, 229^237, 242^254, 261^269, dis-
play the sensitivity to RNases T1 and ONE and represent
potential target sites for antisense oligonucleotides in this do-
main (Fig. 2).
Domain II is connected to domain I by a single-stranded
sequence (281^292). Domain II seems to be highly structured
which is indicated by a number of RNase V1 cuts found with-
in this region. Nucleotides 293^300/310^317, 318^323/333^
338, 416^419/353^359 (Fig. 1D) form helices cut by RNase
V1. These structures contain sites sensitive to RNases ONE
and T1 cleavage (positions 281^292, 301^310, 324^332, 360^
366, 380^383, 387^396, 434^442, 454^471, 499^502).
A-U-rich domain III seems to have a very loose structure.
In this domain, the probing experiments did not reveal any
de¢nite structure elements. All tested nucleases produced dif-
fuse cleavage patterns and a number of artefactual reverse
transcriptase stops. According to computer modeling, residues
570^634 may form a stem-loop structure containing bulged
bases and internal loops. Only nucleotides 591^594 and 641^
646 seem to form stable helices.
For targeting the PGY1/MDR1 mRNA, we used the follow-
ing antisense oligonucleotides: AS-1, complementary to resi-
dues 122^137 (corresponding to nucleotides 34 to +16, where
+1 is A in AUG codon), AS-2, complementary to residues
150^165 (+10 to +25), and AS-3, complementary to nucleo-
tides 319^334 (+178 ^ +194) (Fig. 2). We designed these anti-
sense oligonucleotides taking into account our data [32,33]
and data of other studies [34] evidencing that oligonucleotides
bind to the structures where e¡ective formation of nucleation
complexes is possible. The nucleation complex can be formed
with 4^6 nucleotides long single-stranded sequences [32] with
further invasion of the oligonucleotide into RNA structure
and formation of extended heteroduplex.
We investigated hybridization of the chosen oligonucleo-
tides to PGY1/MDR1 mRNA by £uorescence-monitored titra-
tion of the 5P-end pyrene-labeled antisense oligonucleotides
with an increasing concentration of RNA. It is known that
the £uorescence of pyrene-labeled oligonucleotides is strongly
a¡ected by duplex formation [35]. Binding of pyrene-labeled
AS-1, AS-2 or AS-3 to the RNA resulted in enhancement of
the pyrene £uorescence (Fig. 3). Fluorescence of random pyr-
ene-labeled oligonucleotide was not a¡ected by the RNA
(data not shown). The association constants (Kx) for oligonu-
cleotides AS-1, AS-2 and AS-3 derived from £uorescence ti-
tration data using the modi¢ed Shtern^Folmer equation are
106 M31, 0.87U107 M31 and 0.7U106 M31, respectively.
4. Discussion
The key step in the design of antisense oligonucleotides is
the identi¢cation of the optimal target sequences in the RNA.
In the present study, we combined computer simulation with
enzymatic probing to build a model of secondary structure of
the PGY1/MDR1 mRNA fragment and to identify the RNA
regions that might be e⁄cient targets for antisense oligonu-
cleotides. We assumed that the investigated RNA fragment
has the structure similar to that of the corresponding region
in the full length PGY1/MDR1 mRNA. This assumption is
supported by studies of hybridization of antisense oligonu-
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Fig. 1. Probing of the structure of in vitro transcript of human PGY1/MDR1 RNA fragment with RNases T1, ONE and V1 in physiological
conditions (50 mM HEPES, pH 7.0, containing 200 mM KCl, 5 mM MgCl2). Autoradiographs of 6% denaturing PAGE fractionation of
cDNA products obtained by primer-directed reverse transcription of RNase-treated and control RNA. A: Extension of 32P-labeled oligonucleo-
tide 130-RT, B: extension of 32P-labeled oligonucleotide 240-RT, C: extension of 32P-labeled oligonucleotide 340-RT, D: extension of 32P-la-
beled oligonucleotide 450-RT. K: Incubation control. Lanes C, U, A, G, sequencing products generated by extension of the same primer in the
presence of ddGTP, ddATP, ddTTP and ddCTP, respectively. Lanes 1^6, primer extension of in vitro transcribed PGY1/MDR1 mRNA treated
with RNases: 1, 2: RNase T1 (0.1^0.05 U/ml); 3, 4: RNase ONE (0.05^0.03 U/ml); 5, 6: RNase V1 (0.1^0.05 U/ml). PGY1/MDR1 mRNA se-
quence is indicated on the left panel.
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cleotides with the long mRNA and its shortened versions [10].
There is the only computer-derived fold of full length PGY1/
MDR1 mRNA obtained using FOLD program, which ¢nds a
structure with minimum energy and with a maximum number
of bases paired intramolecularly [36]. Results of these calcu-
lations show that PGY1/MDR1 RNA is extensively folded: in
the predicted model, 62% of the bases are paired. In some
parts, the structure of the 5P-proximal region calculated in
[36] seems to be similar to that shown in Fig. 2. Both struc-
tures are built of three domains. According to our data, the
structure of the 5P-terminal fragment of PGY1/MDR1 mRNA
is more open and contains a number of loops of di¡erent
nature. In the presented structure, the AUG codon is located
in the octanucleotide loop (Fig. 2). This is in accordance with
the available experimental data about accessibility of the ini-
tiation translation site to antisense oligonucleotides [9^
11,35,37].
The proposed structure of PGY1/MDR1 mRNA fragment
is in agreement with published data on testing antisense oli-
gonucleotides [9,11] and the data of the studies on hybrid-
ization of semi-random oligonucleotides library with PGY1/
MDR1 mRNA followed by cleavage with RNAse H [10].
The most e⁄cient hybridization with the PGY1/MDR1
mRNA was detected within the region 126^175 (A of AUG
codon corresponds to position 141) that includes unstructured
sequences and unstable secondary structure elements in
the proposed model. Oligonucleotides complementary to
sequences 117^137, 131^152, 162^181 of PGY1/MDR1
mRNA were shown to suppress the P-gp function for
60^90% [10]. However, several attempts to inhibit PGY1/
MDR1 gene expression by antisense oligonucleotides failed
[38]. Oligonucleotides complementary to the sequences 31^
50, 57^76, 87^106, 177^196 demonstrated poor antisense ac-
tivity [10]. According to our data, these oligonucleotides are
Fig. 2. Secondary structure of the 5P-terminal fragment of PGY1/MDR1 mRNA. (b, a) indicate sites strongly or weakly reactive to RNase
ONE; ( ) indicate sites strongly or weakly reactive to RNase V1; ( ) indicate sites strongly or weakly reactive to RNase T1. Pseudo-
knott forming sequences are connected by lines.
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complementary to double-stranded regions of the PGY1/
MDR1 mRNA.
Antisense oligonucleotides AS-1, AS-2 and AS-3 were de-
signed to target RNA in the structure shown in Fig. 2. Target
sequences for the oligonucleotides contain 6^8 nucleotides
long single-stranded regions to initiate the binding [32^34].
The tested oligonucleotides show quite an e⁄cient hybridiza-
tion: association constants (Kx) are 106 M31, 0.87U107 M31
and 0.7U106 M31 for oligonucleotides AS-1, AS-2 and AS-3,
respectively. The obtained association constants are compara-
ble with those of the tight binding antisense oligonucleotides
that e⁄ciently down regulate gene expression [34,39]. For ex-
ample, the association constants for oligonucleotides that ef-
fectively bind and unfold the acceptor and T8C stems of
yeast tRNAPhe are within the range of 105 M31 [32]. The
most e⁄cient binding is observed for oligonucleotide AS-2,
complementary to the region +10 to +25 (150^165), which
comprises two short single-stranded sequences separated by
a short stem. AS-1 and AS-3 show similar binding e⁄ciency.
Their targets include single-stranded sequences adjacent to
stem regions with mismatches. Antisense oligonucleotide [36]
complementary to sequence +18 to +33, that is close to the
target of oligonucleotide AS-2, was the only e¡ective in down
regulation of P-gp expression in MCF-7/ADR cells.
The obtained results evidence that the built model of the
PGY1/MDR1 mRNA fragment allows the prediction of the
sequences accessible for e⁄cient oligonucleotide hybridiza-
tion. Derivatization of the identi¢ed antisense oligonucleo-
tides with the reactive groups and groups providing e⁄cient
cellular uptake may result in the development of e⁄cient in-
hibitors of PGY1/MDR1 mRNA expression which might be
of therapeutics value.
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